Monday April 12, 2021 0 comments
BOULDER and CAMBRIDGE, Mass. -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer John Robinson.
"Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically driven diseases," said Andrew Robbins, Cogent Biosciences president and CEO.
"I am thrilled to welcome John onboard as Cogent Biosciences' chief scientific officer. John's expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists.
“Given the team's impressive experience and accomplishments, we are excited for Cogent Biosciences' future and the opportunity to expand our pipeline and deliver novel precision therapies for patients."
With an exceptional track record of innovation, the Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions.
The Cogent Research Team is based in Boulder.
"I am excited to join Cogent Biosciences and create a new center of excellence for small molecule discovery and development in the greater Boulder/Denver community," said Robinson.
"With strong support from Andy and the Cogent board, I am confident we can build upon our already impressive team of scientists to create a portfolio of new medicines which can bring hope to patients in need."
Robinson joins the Cogent Biosciences team from Pfizer where he most recently served as Vice President, Medicinal Chemistry. For more than 15 years prior to his time at Pfizer, he was a senior member of the Array BioPharma scientific leadership team, a group responsible for developing over 25 Investigational New Drug (IND) applications including five U.S. Food and Drug Administration (FDA) approved medicines: MEKTOVI® (binimetinib), TUKYSA® (tucatinib), VITRAKVI® (larotrectinib), Retevmo™ (selpercatinib) and Koselugo™ (selumetinib).
Robinson holds a BS from Indiana University of Pennsylvania and a PhD from the University of Delaware.